Pharming Group (PHAR) Competitors $10.26 +0.07 (+0.69%) Closing price 04:00 PM EasternExtended Trading$10.31 +0.05 (+0.49%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHAR vs. ALVO, MIRM, CPRX, GMTX, AMRX, NAMS, RARE, OGN, APLS, and IBRXShould you be buying Pharming Group stock or one of its competitors? The main competitors of Pharming Group include Alvotech (ALVO), Mirum Pharmaceuticals (MIRM), Catalyst Pharmaceuticals (CPRX), Gemini Therapeutics (GMTX), Amneal Pharmaceuticals (AMRX), NewAmsterdam Pharma (NAMS), Ultragenyx Pharmaceutical (RARE), Organon & Co. (OGN), Apellis Pharmaceuticals (APLS), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry. Pharming Group vs. Its Competitors Alvotech Mirum Pharmaceuticals Catalyst Pharmaceuticals Gemini Therapeutics Amneal Pharmaceuticals NewAmsterdam Pharma Ultragenyx Pharmaceutical Organon & Co. Apellis Pharmaceuticals ImmunityBio Alvotech (NASDAQ:ALVO) and Pharming Group (NASDAQ:PHAR) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk. Is ALVO or PHAR more profitable? Alvotech has a net margin of 16.42% compared to Pharming Group's net margin of -4.14%. Pharming Group's return on equity of -6.01% beat Alvotech's return on equity.Company Net Margins Return on Equity Return on Assets Alvotech16.42% -36.37% 12.70% Pharming Group -4.14%-6.01%-3.23% Do analysts recommend ALVO or PHAR? Alvotech presently has a consensus price target of $14.00, indicating a potential upside of 45.68%. Pharming Group has a consensus price target of $30.00, indicating a potential upside of 192.40%. Given Pharming Group's higher possible upside, analysts clearly believe Pharming Group is more favorable than Alvotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alvotech 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Pharming Group 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, ALVO or PHAR? Alvotech has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500. Comparatively, Pharming Group has a beta of 0.02, meaning that its stock price is 98% less volatile than the S&P 500. Do institutionals and insiders believe in ALVO or PHAR? 0.0% of Pharming Group shares are held by institutional investors. 0.5% of Alvotech shares are held by insiders. Comparatively, 2.1% of Pharming Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media favor ALVO or PHAR? In the previous week, Alvotech had 1 more articles in the media than Pharming Group. MarketBeat recorded 5 mentions for Alvotech and 4 mentions for Pharming Group. Pharming Group's average media sentiment score of 1.04 beat Alvotech's score of 0.53 indicating that Pharming Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alvotech 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Pharming Group 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, ALVO or PHAR? Pharming Group has lower revenue, but higher earnings than Alvotech. Pharming Group is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlvotech$491.98M5.89-$231.86M$0.3725.97Pharming Group$297.20M2.37-$11.84M-$0.20-51.30 SummaryAlvotech beats Pharming Group on 8 of the 15 factors compared between the two stocks. Get Pharming Group News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHAR vs. The Competition Export to ExcelMetricPharming GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$698.27M$3.07B$5.70B$9.51BDividend YieldN/A2.36%4.69%4.01%P/E Ratio-51.308.6721.1920.14Price / Sales2.37328.69461.30104.37Price / Cash137.4942.7636.2258.56Price / Book3.168.378.665.87Net Income-$11.84M-$55.19M$3.25B$258.55M7 Day Performance-0.10%5.89%4.20%2.23%1 Month Performance-6.30%17.63%10.82%12.76%1 Year Performance20.71%5.09%34.70%19.36% Pharming Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHARPharming Group2.2919 of 5 stars$10.26+0.7%$30.00+192.4%+18.4%$698.27M$297.20M-51.30280News CoveragePositive NewsUpcoming EarningsHigh Trading VolumeALVOAlvotech2.6708 of 5 stars$8.64+0.1%$16.00+85.2%-21.0%$2.60B$491.98M23.351,032MIRMMirum Pharmaceuticals3.8597 of 5 stars$51.95+0.0%$65.50+26.1%+33.5%$2.57B$336.89M-32.27140Positive NewsCPRXCatalyst Pharmaceuticals4.9232 of 5 stars$21.01-0.1%$32.83+56.3%+20.0%$2.57B$491.73M13.3880News CoveragePositive NewsAnalyst RevisionGMTXGemini TherapeuticsN/A$57.770.0%N/A+32.1%$2.50BN/A-57.7730High Trading VolumeAMRXAmneal Pharmaceuticals3.1391 of 5 stars$7.91-0.8%$11.60+46.6%+8.0%$2.50B$2.83B-197.708,100NAMSNewAmsterdam Pharma3.7871 of 5 stars$22.56+1.6%$41.30+83.1%+23.8%$2.49B$45.56M-12.004RAREUltragenyx Pharmaceutical4.3623 of 5 stars$26.39+0.3%$83.64+216.9%-39.5%$2.49B$560.23M-4.491,294Upcoming EarningsGap DownHigh Trading VolumeOGNOrganon & Co.4.7689 of 5 stars$9.43-0.4%$18.00+91.0%-53.5%$2.46B$6.40B3.274,000APLSApellis Pharmaceuticals4.1447 of 5 stars$19.28-1.0%$40.00+107.5%-46.3%$2.45B$781.37M-10.77770Upcoming EarningsIBRXImmunityBio2.1358 of 5 stars$2.68-2.5%$12.25+357.1%-43.5%$2.43B$14.74M-4.62590News CoverageAnalyst Forecast Related Companies and Tools Related Companies ALVO Competitors MIRM Competitors CPRX Competitors GMTX Competitors AMRX Competitors NAMS Competitors RARE Competitors OGN Competitors APLS Competitors IBRX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHAR) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharming Group N.V. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharming Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PHAR Stock Alerts